National Institute for Health and Care Excellence
Centre for Health Technology Evaluation

Pro-forma Response

Executable Model

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab for the treatment of rheumatoid arthritis (review of TA guidance 130, 186, 224, 234 and part review of TA guidance 225 and 247) [ID537]

The economic model enclosed and its contents are confidential and are protected by intellectual property rights, which are owned by the **School for Health and Related Research (ScHARR) at the University of Sheffield**. It has been sent to you for information only. It cannot be used for any other purpose than to inform your understanding of the appraisal. Accordingly, neither the model nor its contents should be divulged to anyone other than those individuals within your organisation who need to see to them to enable you to prepare your response. Those to whom you do show the documents must be advised they are bound by the terms of the Confidentiality Acknowledgement and Undertaking Form that has already been signed and returned to the Institute by your organisation.

You may not make copies of the file and you must delete the file from your records when the appraisal process, and any possible appeal, are complete. If asked, you must confirm to us in writing that you have done so. You may not publish it in whole or part, or use it to inform the development of other economic models.

The model must not be re-run for purposes other that the testing of its reliability.

Please set out your comments on reliability in writing providing separate justification, with supporting information, for each specific comment made. Where you have made an alteration to the model details of how this alteration was implemented in the model (e.g. in terms of programme code) must be given in sufficient detail to enable your changes to be replicated from the information provided. Please use the attached pro-forma to present your response.

Please prepare your response carefully. Responses which contain errors or are internally inconsistent (for example where we are unable to replicate the results claimed by implementing the changes said to have been made to the model) will be rejected without further consideration.

Results from amended versions of the model will only be accepted if their purpose is to test robustness and reliability of the economic model. Results calculated purely for the purpose of using alternative inputs will not be accepted.

No electronic versions of the economic model will be accepted with your response.

Responses should be provided in tabular format as suggested below (please add further tables if necessary).

December 2013

Issue 1 Population Age

Description of problem	Description of proposed amendment	Result of amended model or expected impact on the result (if applicable)
The minimum age for an “acceptable” simulated individual is hardcoded to 50 years (pop_min_age). This means that out of the Normal distribution with mean 56 years and SD 12 years, only a part of distribution is being considered in the model.	No minimum should be coded in the Pop_min_age.	When corrected, the implication of this in the model is an increase in the number of incremental QALYs gained for the bDMARD strategies and a drop in the ICER by an average of £5,000 across all comparisons.